Teleflex Launches National Ad Campaign — “Pit Stop” — to Raise Awareness of the UroLift® System as a Treatment for Enlarged Prostate
February 06 2023 - 6:30AM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced the launch of a new national
advertising campaign to raise awareness of the UroLift® System, the
leading minimally invasive, outpatient treatment in the United
States for enlarged prostate, also known as benign prostatic
hyperplasia (BPH). The racetrack-themed “Pit Stop” campaign takes a
humorous approach and emphasizes the need to “take care of #1.” The
campaign can be viewed at UroLift.com.
BPH is a non-cancerous enlargement of the prostate that occurs
naturally for some men as they age. The enlarged prostate can press
on and block the urethra, causing bothersome urinary symptoms,
including frequency and urgency, and interrupted sleep.1
The new campaign consists of nationally televised spots and
related digital ads connecting viewers to UroLift.com to learn more
about the minimally invasive treatment option for an enlarged
prostate.
“So many men are still putting off a visit to their urologist
about their BPH despite suffering from symptoms and putting their
bladder health at risk,” said Steven Gange, M.D., F.A.C.S., of
Summit Urology Group and Associate Medical Director of the Teleflex
Interventional Urology Business Unit. “The UroLift® System is an
effective minimally invasive treatment that can provide rapid
relief of BPH symptoms, and may free men from taking ongoing
medications.”2
“We are excited to help raise awareness of BPH and the UroLift®
System as the number one minimally invasive treatment solution of
choice for urologists and their patients in the U.S., with more
than 400,000 men treated around the world,” said Bryan Holmes,
Global Vice President, Marketing and Business Development of the
Teleflex Interventional Urology Business Unit.3-4
About the UroLift®
System
The UroLift® System is a minimally invasive treatment for lower
urinary tract symptoms due to benign prostatic hyperplasia (BPH).
It is indicated for the treatment of symptoms of an enlarged
prostate up to 100 cc in men 45 years or older (50 years outside
U.S.). The UroLift® permanent implants, which can be delivered
during an outpatient procedure, relieve prostate obstruction
without heating, cutting, destruction of, or removing prostate
tissue.5 The UroLift® System can be used to treat a broad spectrum
of anatomies, including obstructive median lobe.6 It is the only
leading BPH procedure shown to not cause new onset, sustained
erectile or ejaculatory dysfunction.*2,7-8 The 5-year L.I.F.T.
study results demonstrate UroLift® System durability with a
surgical retreatment rate of about 2-3% per year and 13.6% total
over 5 years.2 Most common adverse events are temporary and can
include hematuria, dysuria, micturition urgency, pelvic pain, and
urge incontinence.9 Rare side effects, including bleeding and
infection, may lead to a serious outcome and may require
intervention. Individual results may vary. The prostatic urethral
lift procedure (using the UroLift® System) is recommended for the
treatment of BPH in both the 2021 American Urological Association
and 2022 European Association of Urology clinical guidelines. More
than 400,000 men have been treated with the UroLift® System in
select markets worldwide.4 Learn more at UroLift.com. Rx only.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose- driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular access, interventional cardiology and radiology,
anesthesia, emergency medicine, surgical, urology and respiratory
care. Teleflex employees worldwide are united in the understanding
that what we do every day makes a difference. For more information,
please visit Teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management’s current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Contacts:
Teleflex Incorporated:
Lawrence KeuschVice President, Investor
Relations and Strategy Development
John Hsu, CFAVice President, Investor
RelationsInvestors.teleflex.com610-948-2836
Media:Nicole
Osmernicole@healthandcommerce.com650-454-0504
* No instances of new sustained erectile or ejaculatory
dysfunction in the L.I.F.T. pivotal study.
References:
- Speakman, BJUI 2014.
- Roehrborn, Can J Urol 2017.
- U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22
FINAL), which is in part based on Symphony Health PatientSource®
2018–21, as is and with no representations/warranties, including
accuracy or completeness.
- Management estimate based on product sales as of December 2022.
Data on file, Teleflex Interventional Urology.
- Shore, Can J Urol 2014.
- Rukstalis, Prostate Cancer and Prostatic Dis 2018.
- AUA BPH Guidelines 2003, 2021.
- McVary, Urology 2019.
- Roehrborn, J Urol 2013.
Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®,
QuikClot®, Rüsch®, UroLift®, and Weck® — trusted brands united by a
common sense of purpose.
Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling,
QuikClot, Rüsch, UroLift, and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.
© 2023 Teleflex Incorporated. All rights reserved. MAC02635-01
Rev A
Teleflex (NYSE:TFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Jul 2023 to Jul 2024